Anzeige
Mehr »
Mittwoch, 27.08.2025 - Börsentäglich über 12.000 News
Breaking: AlsetAI zündet nächste Stufe - Neue Allianz mit CHIP Datacentres & Hochkarätige Vorstände markieren Wendepunkt
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: 896047 | ISIN: US09058V1035 | Ticker-Symbol: BO1
Tradegate
26.08.25 | 21:13
7,270 Euro
-1,46 % -0,108
1-Jahres-Chart
BIOCRYST PHARMACEUTICALS INC Chart 1 Jahr
5-Tage-Chart
BIOCRYST PHARMACEUTICALS INC 5-Tage-Chart
RealtimeGeldBriefZeit
7,2987,48007:05
7,2987,48007:03

Aktuelle News zur BIOCRYST PHARMACEUTICALS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
12.08.BIOCRYST PHARMACEUTICALS INC - S-8, Securities to be offered to employees in employee benefit plans1
11.08.BioCryst's chief R&D officer to depart for CEO role elsewhere2
11.08.BIOCRYST PHARMACEUTICALS INC - 8-K, Current Report2
11.08.BioCryst Pharmaceuticals, Inc.: BioCryst Announces Departure of Dr. Helen Thackray504RESEARCH TRIANGLE PARK, N.C., Aug. 11, 2025 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that Dr. Helen Thackray, chief research and development officer, will...
► Artikel lesen
06.08.BioCryst Pharmaceuticals, Inc.: BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)92RESEARCH TRIANGLE PARK, N.C., Aug. 06, 2025 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the compensation committee of BioCryst's board of directors granted...
► Artikel lesen
04.08.BioCryst targets $1B ORLADEYO peak and $700M cash by 2027 as leadership shifts and pipeline advances8
BIOCRYST PHARMACEUTICALS Aktie jetzt für 0€ handeln
04.08.BioCryst Q2 2025 slides: ORLADEYO demand surges, profitability accelerates7
04.08.BioCryst: Hohe ORLADEYO-Nachfrage beschleunigt Profitabilität17
04.08.BioCryst: EPS übertrifft Schätzungen um 0,14 $ - Umsatz besser als erwartet7
04.08.BioCryst Pharmaceuticals Non-GAAP EPS of $0.15 beats by $0.12, revenue of $163.4M beats by $13.58M3
01.08.Earnings Outlook For BioCryst Pharma4
01.08.BioCryst Pharmaceuticals Q2 2025 Earnings Preview10
31.07.BioCryst Pharmaceuticals Before Q2 Earnings: How to Play the Stock6
31.07.BioCryst appoints Charlie Gayer to succeed Jon Stonehouse as CEO1
31.07.BioCryst Pharmaceuticals announces leadership transition as CEO plans retirement4
31.07.BioCryst Pharmaceuticals, Inc.: BioCryst Announces Charlie Gayer to Succeed Jon Stonehouse as Chief Executive Officer Upon his Retirement in December199RESEARCH TRIANGLE PARK, N.C., July 31, 2025 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that its president and chief executive officer, Jon Stonehouse, has informed...
► Artikel lesen
31.07.BIOCRYST PHARMACEUTICALS INC - 8-K, Current Report1
24.07.RBC Capital: BioCryst-Aktie vor Quartalszahlen unterbewertet10
24.07.BioCryst stock undervalued ahead of Q2 earnings, says RBC Capital3
21.07.BioCryst Pharmaceuticals, Inc.: BioCryst to Report Second Quarter 2025 Financial Results on August 42
Weiter >>
95 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1